![](/img/cover-not-exists.png)
Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
Li, Sini, Peng, Liubao, Tan, Chongqing, Zeng, Xiaohui, Wan, Xiaomin, Luo, Xia, Yi, Lidan, Li, Jianhe, De Mello, Ramon AndradeVolume:
15
Journal:
PLOS ONE
DOI:
10.1371/journal.pone.0232240
Date:
May, 2020
File:
PDF, 891 KB
2020